Cognitive effects of systemic therapy in patients with breast cancer

Breast Care

Volumn 4, Issue 3, 2009, Pages 177-182

  Berndt, Ute ^a   Leplow, Bernd ^b   Kantelhardt, Eva ^a   Thomssen, Christoph ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Institut für Psychologie der Martin Luther Universität Halle Wittenberg   (Germany)

Author keywords

Breast cancer; Chemotherapy; Cognitive side effects; Endocrine therapy

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; INOSITOL; PLACEBO; PROGESTERONE; TAMOXIFEN;

BASAL GANGLION; BRAIN BLOOD FLOW; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG MECHANISM; DRUG MEGADOSE; ESTROGEN SYNTHESIS; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MEMORY DISORDER; MENOPAUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REVIEW; SIDE EFFECT; VERBAL MEMORY; VISUAL MEMORY;

EID: 67651108808     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000221543     Document Type: Review

References (59)

1. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers: 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004;101:466-75.
2. Tannock IF, Ahles TA, Ganz PA, van Dam FS: Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233-9.
3. Shilling V, Jenkins V, Morris R, Deutsch G, Bloom-field D: The effects of adjuvant chemotherapy on cognition in women with breast cancer - preliminary results of an observational longitudinal study. Breast 2005;14:142-50.
4. Morse R, Rodgers J, Verrill M, Kendell K: Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur J Cancer 2003;39:2288-97.
5. Paraska C, Bender CM: Cognitive dysfunction following adjuvant chemotherapy for breast cancer: two case studies. Oncol Nurs Forum 2003;30:473-8.
6. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-701.
7. Wienecke M, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncol 1995;4:61-6.
8. Van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-8.
9. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-50.
10. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA: The cognitive sequelae of standarddose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004;100:2292-9.
11. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-1.
12. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM: Neuropsy-chologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-93.
13. Saykin AJ, Ahles TA, Schoenfeld JD: Grey matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc 2003;9:246.
14. Silverman DH, Castellon SA, Abraham L, Dy CJ, Pio BS, Ganz PA: Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive changes. Proc Am Soc Clin Oncol 2003;22:12.
15. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS: Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001;51:159-65.
16. Silvermann Dh, Dy CJ, Castellon SA Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Cancer Res Treat 2007;103:303-11.
17. Ludwig H, Strasser K: Symptomatology of anemia. Semin Oncol 2001;28:7-14.
18. Jacobsen PB, Thors CL, Cawley M, Ax E, Grendys EC: Relation of decline in haemoglobin to cognitive functioning and fatigue during chemotherapy treatment. Proc Am Soc Clin Oncol 2002;21:386.
19. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;15;21:4175-83.
20. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam F: Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002;13:1387-97.
21. Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, Wyld D, Thomson D: Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology 2000;9:29-39.
22. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Münzel K: Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007;109:1905-1913.
23. Shilling V, Jenkins V: Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007;11:6-15.
24. Shilling V, Jenkins V, Trapala I S: The misclassification of chemofog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 2006;27:1-5.
25. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E: A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006;20:76-89.
26. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA: The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59:60-70.
27. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer G: A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005;104:2222-33.
28. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, et al.: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006;94:828-34.
29. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA: Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002;287:742-8.
30. Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K: A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med 2001;161:1703-8.
31. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006;15:422-30.
32. Sherwin BB: Estrogen and cognitive functioning in women. Endocr Rev 2003;24:133-51 (review).
33. Behl C, Moosmann B: Neuroprotektive Aktivitäten von Estrogen. Nachr Chem 2001;49:332-6.
34. Wenderlein MJ: Aromatasehemmer riskant für das Gehirn? Geburtsh Frauenheilk 2005;65:144-8.
35. McEwen BS, Alves SE: Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307.
36. Foy MR: 17beta-estradiol: effect on CA1 hippoc-ampal synaptic plasticity.. Neurobiol Learn Mem 2001;76:239-52 (review).
37. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ: Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 2004; 21:364-71.
38. Shughrue PJ, Merchenthaler I: Estrogen is more than just a 'sex hormone': novel sites for estrogen action in the hippocampus and cerebral cortex. Front Neuroendocrinol 2000;21:95-101.
39. Woolley CS: Electrophysiolocgical and celluar effects oft estrogen and neuronal function. Crit Review Neurobiol1999;13:1-20.
40. Riecher-Rösler A: Östrogene und Psychopharmaka. Östrogene in der Psychiatrie - Psychopharmaka in der Gynäkologie? Ars Medici 2008;25/26:1118-21.
41. Rao ML, Kölsch H: Einfluss von Östradiol-17p auf die Hirnentwicklung und seine Eigenschaften als Neuroprotektivum. J Neurol Neurochir Psychiatr 2002;3:34-9.
42. Maurer K, Häfner H: Die Östrogenhypothese der Schizophrenie - Übersicht und aktueller Stand der Forschung. J Neurol Neurochir Psychiatr 2002; 3:26-31.
43. McEwen BS: Estrogen effects on the brain: much more than sex. Karger Gazette Hormones 2005; 66:1-9.
44. Bonuccelli U, Melis GB, Paoletti AM, Fioretti P, Murri L, Muratorio A: Unbalanced progesterone and estradiol secretion in catamenial epilepsy. Epilepsy Res 1989;3:100-6.
45. Belfort MA, Saade GR, Snabes M, Dunn R, Moise KJ Jr, Cruz A, Young R: Hormonal status effects the reactivity of cerebral vasculature. Am J Obstet Gynecol 1995;172:1273-8.
46. Bishop J, Simpkins JW: Role of estrogens in peripheral and cerebral glucose utilization. Rev Neurosci 1992;3:121-37.
47. Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ock-ene JK, Shumaker SA: Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metable 2006;91:1802-10.
48. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C: Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 2005;30:309-15.
49. Sherwin BB, Henry JF: Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol 2008;29:88-113.
50. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004;13:61-6.
51. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL: Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;14:995-8.
52. Palmer JL, Trotter T, Joy AA, Carlson LE: Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2008;2:275-82.
53. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S: Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology 2008; Epub ahead of print.
54. Ernst T, Chang L, Cooray D, Salvador C, Jovicich J, Walot I, Boone K, Chlebowski R: The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002;17;94:592-7.
55. Chang L, Ernst T, Poland RE, Jenden DJ: In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 1996;58:2049-56.
56. Paganini-Hill A, Clark LJ: Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;64:165-76.
57. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K: Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 2008;1;113:2431-9.
58. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ: Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 2008;9:953-61.
59. Hadji P, Ziller V, Holzhauer W, Ziller M, Kalder M, Wagner U: Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer. Breast Cancer Res Treat 2007; 106:146-50.